These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 37302583)

  • 1. Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures.
    Fan R; Chen L; Zhao S; Yang H; Li Z; Qian Y; Ma H; Liu X; Wang C; Liang X; Bai J; Xie J; Fan X; Xie Q; Hao X; Wang C; Yang S; Gao Y; Bai H; Dou X; Liu J; Wu L; Jiang G; Xia Q; Zheng D; Rao H; Xia J; Shang J; Gao P; Xie D; Yu Y; Yang Y; Gao H; Liu Y; Sun A; Jiang Y; Yu Y; Niu J; Sun J; Wang H; Hou J
    J Hepatol; 2023 Oct; 79(4):933-944. PubMed ID: 37302583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis.
    Fan R; Papatheodoridis G; Sun J; Innes H; Toyoda H; Xie Q; Mo S; Sypsa V; Guha IN; Kumada T; Niu J; Dalekos G; Yasuda S; Barnes E; Lian J; Suri V; Idilman R; Barclay ST; Dou X; Berg T; Hayes PC; Flaherty JF; Zhou Y; Zhang Z; Buti M; Hutchinson SJ; Guo Y; Calleja JL; Lin L; Zhao L; Chen Y; Janssen HLA; Zhu C; Shi L; Tang X; Gaggar A; Wei L; Jia J; Irving WL; Johnson PJ; Lampertico P; Hou J
    J Hepatol; 2020 Dec; 73(6):1368-1378. PubMed ID: 32707225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of acknowledged hepatocellular carcinoma risk scores in high-risk hepatitis C patients with sustained virological response.
    Qiu L; Xu S; Qiu Y; Liu Y; Zhang J
    J Viral Hepat; 2023 Jun; 30(6):559-566. PubMed ID: 36890735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of the hepatocellular carcinoma early detection screening algorithm Doylestown and aMAP in a cohort of Chinese with cirrhosis.
    Qian Y; Li L; Ma L; Ji R; Ying S; Zhou J; Fu L; Yang G
    J Clin Lab Anal; 2022 Apr; 36(4):e24296. PubMed ID: 35218083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Risk Prediction Model for Hepatocellular Carcinoma Progression of Indeterminate Nodules in Hepatitis B Virus-Related Cirrhotic Liver.
    Cho HJ; Kim B; Lee JD; Kang DR; Kim JK; Lee JH; Shin SJ; Lee KM; Yoo BM; Lee KJ; Kim SS; Cheong JY; Cho SW
    Am J Gastroenterol; 2017 Mar; 112(3):460-470. PubMed ID: 27779194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-free DNA testing for early hepatocellular carcinoma surveillance.
    Chen L; Wu T; Fan R; Qian YS; Liu JF; Bai J; Zheng B; Liu XL; Zheng D; Du LT; Jiang GQ; Wang YC; Fan XT; Deng GH; Wang CY; Shen F; Hu HP; Zhang QZ; Ye YN; Zhang J; Gao YH; Xia J; Yan HD; Liang MF; Yu YL; Sun FM; Gao YJ; Sun J; Zhong CX; Wang Y; Wang H; Kong F; Chen JM; Wen H; Wu BM; Wang CX; Wu L; Hou JL; Wang HY
    EBioMedicine; 2024 Feb; 100():104962. PubMed ID: 38184937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B.
    Papatheodoridis GV; Sypsa V; Dalekos GN; Yurdaydin C; Van Boemmel F; Buti M; Calleja JL; Chi H; Goulis J; Manolakopoulos S; Loglio A; Voulgaris T; Gatselis N; Keskin O; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Idilman R; Esteban R; Janssen HLA; Berg T; Lampertico P
    J Hepatol; 2020 Jun; 72(6):1088-1096. PubMed ID: 31981727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B.
    Kaneko S; Kurosaki M; Mashiba T; Marusawa H; Kondo M; Kojima Y; Uchida Y; Fujii H; Akahane T; Yagisawa H; Kusakabe A; Kobashi H; Abe T; Yoshida H; Ogawa C; Furuta K; Tamaki N; Tsuji K; Matsushita T; Izumi N;
    J Med Virol; 2023 Jan; 95(1):e28210. PubMed ID: 36222204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B.
    Liang LY; Lee HW; Wong VW; Yip TC; Tse YK; Hui VW; Lui GC; Chan HL; Wong GL
    Clin Mol Hepatol; 2021 Jul; 27(3):499-509. PubMed ID: 33631920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid biopsy by combining 5-hydroxymethylcytosine signatures of plasma cell-free DNA and protein biomarkers for diagnosis and prognosis of hepatocellular carcinoma.
    Cai Z; Zhang J; He Y; Xia L; Dong X; Chen G; Zhou Y; Hu X; Zhong S; Wang Y; Chen H; Xie D; Liu X; Liu J
    ESMO Open; 2021 Feb; 6(1):100021. PubMed ID: 33508734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and Risk Factors for Hepatocellular Carcinoma in Cirrhosis: The Multicenter Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study.
    Reddy KR; McLerran D; Marsh T; Parikh N; Roberts LR; Schwartz M; Nguyen MH; Befeler A; Page-Lester S; Tang R; Srivastava S; Rinaudo JA; Feng Z; Marrero JA
    Gastroenterology; 2023 Oct; 165(4):1053-1063.e6. PubMed ID: 37429366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.
    Semmler G; Meyer EL; Kozbial K; Schwabl P; Hametner-Schreil S; Zanetto A; Bauer D; Chromy D; Simbrunner B; Scheiner B; Stättermayer AF; Pinter M; Schöfl R; Russo FP; Greenfield H; Schwarz M; Schwarz C; Gschwantler M; Alonso López S; Manzano ML; Ahumada A; Bañares R; Pons M; Rodríguez-Tajes S; Genescà J; Lens S; Trauner M; Ferenci P; Reiberger T; Mandorfer M
    J Hepatol; 2022 Apr; 76(4):812-821. PubMed ID: 34871626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis.
    Ganne-Carrié N; Chaffaut C; Bourcier V; Archambeaud I; Perarnau JM; Oberti F; Roulot D; Moreno C; Louvet A; Dao T; Moirand R; Goria O; Nguyen-Khac E; Carbonell N; Antonini T; Pol S; de Ledinghen V; Ozenne V; Henrion J; Péron JM; Tran A; Perlemuter G; Amiot X; Zarski JP; Beaugrand M; Chevret S;
    J Hepatol; 2018 Dec; 69(6):1274-1283. PubMed ID: 30092234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular Carcinoma Risk Scores Predict Patients Under Surveillance at Low Risk of Benefit and High Risk of Harm.
    Curran C; Priest M; Datta S; Forrest EH; Stanley AJ; Barclay ST
    Dig Dis Sci; 2023 Mar; 68(3):770-777. PubMed ID: 36376575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study.
    Ji J; Wang H; Li Y; Zheng L; Yin Y; Zou Z; Zhou F; Zhou W; Shen F; Gao C
    PLoS One; 2016; 11(4):e0153227. PubMed ID: 27070780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
    Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. External Validation of aMAP Hepatocellular Carcinoma Risk Score in Patients With Chronic Hepatitis B-Related Cirrhosis Receiving ETV or TDF Therapy.
    Gui H; Huang Y; Zhao G; Chen L; Cai W; Wang H; Guo Q; Xie Q
    Front Med (Lausanne); 2021; 8():677920. PubMed ID: 34422855
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: a long-term follow-up study.
    Rodríguez-Díaz JL; Rosas-Camargo V; Vega-Vega O; Morales-Espinosa D; Mendez-Reguera A; Martínez-Tlahuel JL; Gamboa-Domínguez A; Arrieta O
    Clin Oncol (R Coll Radiol); 2007 Apr; 19(3):197-203. PubMed ID: 17359907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Liver Stiffness-Based Etiology-Independent Machine Learning Algorithm to Predict Hepatocellular Carcinoma.
    Lin H; Li G; Delamarre A; Ahn SH; Zhang X; Kim BK; Liang LY; Lee HW; Wong GL; Yuen PC; Chan HL; Chan SL; Wong VW; de Lédinghen V; Kim SU; Yip TC
    Clin Gastroenterol Hepatol; 2024 Mar; 22(3):602-610.e7. PubMed ID: 37993034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients.
    Wu X; Xu X; Zhou J; Sun Y; Ding H; Xie W; Chen G; Ma A; Piao H; Wang B; Chen S; Meng T; Ou X; Yang HI; Jia J; Kong Y; You H
    Clin Mol Hepatol; 2023 Jul; 29(3):747-762. PubMed ID: 37165622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.